KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) EBITDA Margin (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBITDA Margin for 9 consecutive years, with 29.37% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 639.0% to 29.37% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 19.53% through Dec 2025, up 4025.0% year-over-year, with the annual reading at 20.65% for FY2025, 4596.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 29.37% at Twist Bioscience, down from 27.17% in the prior quarter.
  • The five-year high for EBITDA Margin was 21.02% in Q2 2025, with the low at 127.8% in Q1 2022.
  • Average EBITDA Margin over 5 years is 74.77%, with a median of 84.69% recorded in 2022.
  • The sharpest move saw EBITDA Margin crashed -3323bps in 2021, then surged 12615bps in 2025.
  • Over 5 years, EBITDA Margin stood at 108.0% in 2021, then increased by 27bps to 79.38% in 2022, then rose by 25bps to 59.89% in 2023, then soared by 40bps to 35.76% in 2024, then increased by 18bps to 29.37% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 29.37%, 27.17%, and 21.02% for Q4 2025, Q3 2025, and Q2 2025 respectively.